Pashtoon Kasi: ctDNA kinetics is going to be an important variable to look at in patients getting novel immunotherapy drugs like the BOT/BAL on our NEST trial

Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X/Twitter:

”ctDNA kineticsis going to be an important variable to look at in patients getting novel immunotherapy drugs like the BOT/BAL on our NEST trial. The longer you let it brew, the deeper the drop eventual clearance. 100 post-operation. March is Colorectal Cancer Awareness Month.”

Source: Pashtoon Kasi/X